Skip to main content
NCBI home page
Cancer Biomarkers: Section A of Disease Markers logoLink to Cancer Biomarkers: Section A of Disease Markers
. 2017 Feb 27;18(2):169–175. doi: 10.3233/CBM-160120

Role of GSK3β in breast cancer susceptibility

Andrés Felipe Aristizabal-Pachon a,b,*, Willian Orlando Castillo a
PMCID: PMC13020587  PMID: 27983530

Abstract

BACKGROUND:

Breast cancer is one of the principal causes of death among Brazilian women, so it is a challenge to find new and specific early diagnostic markers, using simple and fast procedures. GSK3β gene is an important Wnt signaling regulator involved in β-Catenin degradation. Wnt signaling is associated with initiation and progression process in many tumor types, and alterations in β-Catenin explain only a small proportion of aberrant signaling found in breast cancer, indicating that other Wnt signaling components and/or regulators as GSK3β may be involved.

OBJECTIVE:

The aim of this study was to evaluate the genetic, epigenetic and transcriptional alterations of GSK3β in breast cancer.

METHODS:

Peripheral blood samples from 204 breast cancer and healthy women were collected. Assessment of rs334558 polymorphism was performed by PCR-RFLP, promoter methylation profiles analysis by MS-PCR and qPCR was used to determine GSK3β expression levels.

RESULTS:

The rs334558 polymorphism showed a strong association with aggressive cancer. A significant increase was observed in GSK3β expression level respect to hormone receptors status and tumor size.

CONCLUSION:

The results indicated an inverse relationship between GSK3β performance and tumor progression. This is the first study to relate GSK3β gene with breast cancer in Brazilian population.

Keywords: rs334558, wnt signaling, β-catenin destruction complex, PCR-RFPLs, RT-qPCR

References

  • [1]. Weng B., Wang Q., Lin S., et al., Nasal cavity metastasis of breast cancer: a case report and review of the literature, Int J Clin Exp Pathol 7 (2014), 7028-33. [PMC free article] [PubMed] [Google Scholar]
  • [2]. Brito C., Portela M.C. and Vasconcellos M.T., Survival of breast cancer women in the state of Rio de Janeiro, Southeastern Brazil, Rev Saude Publica 43 (2009), 481-9. [DOI] [PubMed] [Google Scholar]
  • [3]. Aristizabal-Pachon A.F. and Takahashi C.S., Efecto de las alteraciones genéticas, epigenéticas y expresión transcripcional de cadherina-E en la susceptibilidad al cáncer de mama, Biomedica 36 (2016), 593-602. [DOI] [PubMed] [Google Scholar]
  • [4]. Aristizabal-Pachon A.F., de Carvalho T.I., Carrara H.H., et al., Detection of human mammaglobin A mRNA in peripheral blood of breast cancer patients before treatment and association with metastasis, J Egypt Natl Canc Inst 27 (2015), 217-22. [DOI] [PubMed] [Google Scholar]
  • [5]. Lammi L., Arte S., Somer M., et al., Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer, Am J Hum Genet 74 (2004), 1043-50. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [6]. Michils G., Tejpar S., Thoelen R., et al., Large deletions of the APC gene in 15% of mutation-negative patients with classical polyposis (FAP): a Belgian study, Hum Mutat 25 (2005), 125-34. [DOI] [PubMed] [Google Scholar]
  • [7]. Chien A.J., Conrad W.H. and Moon R.T., A Wnt survival guide: from flies to human disease, J Invest Dermatol 129 (2009), 1614-27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [8]. Mishra R., Glycogen synthase kinase 3 beta: can it be a target for oral cancer, Mol Cancer 9 (2010), 144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [9]. Aristizabal-Pachon A.F., Carvalho T.I., Carrara H.H., et al., AXIN2 Polymorphisms, the beta-Catenin Destruction Complex Expression Profile and Breast Cancer Susceptibility, Asian Pac J Cancer Prev 16 (2015), 7277-84. [DOI] [PubMed] [Google Scholar]
  • [10]. Rankin C.A., Sun Q. and Gamblin T.C., Tau phosphorylation by GSK-3beta promotes tangle-like filament morphology, Molecular neurodegeneration 2 (2007), 12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [11]. Ko H.W., Lee H.H., Huo L., et al., GSK3beta inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers Oncotarget (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [12]. Zandi P.P., Belmonte P.L., Willour V.L., et al., Association study of Wnt signaling pathway genes in bipolar disorder, Arch Gen Psychiatry 65 (2008), 785-93. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [13]. Qiu H.J., Lu X.H., Yang S.S., et al., MiR-769 promoted cell proliferation in human melanoma by suppressing GSK3B expression, Biomed Pharmacother 82 (2016), 117-23. [DOI] [PubMed] [Google Scholar]
  • [14]. Munnich N., Wernhart S., Hogstrand C., et al., Expression of the zinc importer protein ZIP9/SLC39A9 in glioblastoma cells affects phosphorylation states of p53 and GSK-3beta and causes increased cell migration, Biometals (2016). [DOI] [PubMed] [Google Scholar]
  • [15]. Ma C., Wang J., Gao Y., et al., The role of glycogen synthase kinase 3beta in the transformation of epidermal cells, Cancer Res 67 (2007), 7756-64. [DOI] [PubMed] [Google Scholar]
  • [16]. Naghibalhossaini F., Zamani M., Mokarram P., et al., Epigenetic and genetic analysis of WNT signaling pathway in sporadic colorectal cancer patients from Iran, Mol Biol Rep 39 (2012), 6171-8. [DOI] [PubMed] [Google Scholar]
  • [17]. Schmittgen T.D. and Livak K.J., Analyzing real-time PCR data by the comparative C(T) method, Nat Protoc 3 (2008), 1101-8. [DOI] [PubMed] [Google Scholar]
  • [18]. Yamulla R.J., Kane E.G., Moody A.E., et al., Testing models of the APC tumor suppressor/beta-catenin interaction reshapes our view of the destruction complex in Wnt signaling, Genetics 197 (2014), 1285-302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [19]. Stamos J.L. and Weis W.I., The beta-catenin destruction complex, Cold Spring Harb Perspect Biol 5 (2013), a007898. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [20]. Blagosklonny M.V., Khalil S., Tan G.A., et al., Activation Status of Wnt/ß-Catenin Signaling in Normal and Neoplastic Breast Tissues: Relationship to HER2/neu Expression in Human and Mouse, PLoS ONE 7 (2012), e33421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [21]. Howe L.R. and Brown A.M., Wnt signaling and breast cancer, Cancer Biol Ther 3 (2004), 36-41. [DOI] [PubMed] [Google Scholar]
  • [22]. Polakis P., The many ways of Wnt in cancer, Current Opinion in Genetics & Development 17 (2007), 45-51. [DOI] [PubMed] [Google Scholar]
  • [23]. Clevers H. and Nusse R., Wnt/beta-catenin signaling and disease, Cell 149 (2012), 1192-205. [DOI] [PubMed] [Google Scholar]
  • [24]. Mukherjee N., Bhattacharya N., Alam N., et al., Subtype-specific alterations of the Wnt signaling pathway in breast cancer: Clinical and prognostic significance, Cancer Science 103 (2012), 210-220. [DOI] [PubMed] [Google Scholar]
  • [25]. Esteller M., Sparks A., Toyota M., et al., Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer, Cancer research 60 (2000), 4366-71. [PubMed] [Google Scholar]
  • [26]. Sturgeon S.R., Balasubramanian R., Schairer C., et al., Detection of promoter methylation of tumor suppressor genes in serum DNA of breast cancer cases and benign breast disease controls, Epigenetics 7 (2012), 1258-67. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [27]. Lin S.Y., Yeh K.T., Chen W.T., et al., Promoter CpG methylation of tumor suppressor genes in colorectal cancer and its relationship to clinical features, Oncol Rep 11 (2004), 341-8. [PubMed] [Google Scholar]
  • [28]. Kalinderi K., Fidani L., Katsarou Z., et al., GSK3beta polymorphisms, MAPT H1 haplotype and Parkinson's disease in a Greek cohort, Neurobiol Aging 32 (2011), 546 e1-5. [DOI] [PubMed] [Google Scholar]
  • [29]. Kwok J.B., Hallupp M., Loy C.T., et al., GSK3B polymorphisms alter transcription and splicing in Parkinson's disease, Ann Neurol 58 (2005), 829-39. [DOI] [PubMed] [Google Scholar]
  • [30]. Li J., Zeng F., Deng J., et al., The Association Between Single Nucleotide Polymorphisms of GSK 3beta Gene and Sporadic Alzheimer's Disease in a Cohort of Southern Chinese Han Population, Neurotox Res 26 (2014), 447-53. [DOI] [PubMed] [Google Scholar]
  • [31]. Chen G., Tang J., Yu G., et al., Meta-analysis demonstrates lack of association of the GSK3B -50C/T polymorphism with risk of bipolar disorder, Mol Biol Rep 41 (2014), 5711-8. [DOI] [PubMed] [Google Scholar]
  • [32]. Gao C., Xiao G. and Hu J., Regulation of Wnt/beta-catenin signaling by posttranslational modifications, Cell Biosci 4 (2014), 13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [33]. Zhu Q., Yang J., Han S., et al., Suppression of glycogen synthase kinase 3 activity reduces tumor growth of prostate cancer in vivo, Prostate 71 (2011), 835-45. [DOI] [PubMed] [Google Scholar]
  • [34]. Farago M., Dominguez I., Landesman-Bollag E., et al., Kinase-inactive glycogen synthase kinase 3beta promotes Wnt signaling and mammary tumorigenesis, Cancer Res 65 (2005), 5792-801. [DOI] [PubMed] [Google Scholar]
  • [35]. Chen J.Q. and Russo J., ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches, Biochim Biophys Acta 1796 (2009), 162-75. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cancer Biomarkers: Section A of Disease Markers are provided here courtesy of SAGE Publications

RESOURCES